The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: The PaLiDo study, a phase II nonrandomized multicenter study.
Karina Dahl Steffensen
Research Funding - Amgen
Marianne Waldstrøm
No relevant relationships to disclose
Niels Pallisgaard
No relevant relationships to disclose
Bente Lund
No relevant relationships to disclose
Kjell Bergfeldt
No relevant relationships to disclose
Jessica Wihl
No relevant relationships to disclose
Nina Keldsen
No relevant relationships to disclose
Christian Marth
No relevant relationships to disclose
Ignace B. Vergote
No relevant relationships to disclose
Anders Kristian Moeller Jakobsen
Research Funding - Amgen